Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A. 2001;98(16):8966–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berry MD, Gainetdinov RR, Hoener MC, Shahid M. Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol Ther. 2017;180:161–80.

Article  CAS  PubMed  Google Scholar 

Raul RG, Marius CH, Mark DB. Trace Amines and their receptors. Pharmacol Rev. 2018;70(3):549.

Article  Google Scholar 

Rutigliano G, Accorroni A, Zucchi R. The case for TAAR1 as a modulator of central nervous system function. Front Pharmacol. 2018;8.

Espinoza S, Salahpour A, Masri B, Sotnikova TD, Messa M, Barak LS, et al. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol. 2011;80(3):416–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A. 2011;108(20):8485–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther. 2008;324(3):948–56.

Article  CAS  PubMed  Google Scholar 

Raab S, Wang H, Uhles S, Cole N, Alvarez-Sanchez R, Künnecke B, et al. Incretin-like effects of small molecule trace amine-associated receptor 1 agonists. Mol Metab. 2016;5(1):47–56.

Article  CAS  PubMed  Google Scholar 

Revel FG, Moreau JL, Gainetdinov RR, Ferragud A, Velázquez-Sánchez C, Sotnikova TD, et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol Psychiatry. 2012;72(11):934–42.

Article  CAS  PubMed  Google Scholar 

Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic potential of TAAR1 agonists in Schizophrenia: evidence from Preclinical models and Clinical studies. Int J Mol Sci. 2021;22(24).

Nair PC, Chalker JM, McKinnon RA, Langmead CJ, Gregory KJ, Bastiampillai T. Trace Amine-Associated receptor 1 (TAAR1): molecular and clinical insights for the treatment of Schizophrenia and related comorbidities. ACS Pharmacol Transl Sci. 2022;5(3):183–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heffernan MLR, Herman LW, Brown S, Jones PG, Shao L, Hewitt MC, et al. Ulotaront: a TAAR1 agonist for the treatment of Schizophrenia. ACS Med Chem Lett. 2022;13(1):92–8.

Article  CAS  PubMed  Google Scholar 

ClinicalTrials.gov. A clinical trial that will study the efficacy and safety of an investigational drug in acutely psychotic people with Schizophrenia. Sumitomo Pharma America, Inc.; 2023. p. NCT04092686. Report No.

ClinicalTrials.gov. A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with Schizophrenia. Sumitomo Pharma America, Inc.; 2023. p. NCT04072354. Report No.

Fultinavičiūtė U. Sumitomo’s schizophrenia drug flops in two Phase III trials ClinicalTrailsarena.com2023 [ https://www.clinicaltrialsarena.com/news/sumitomo-ulotaront-schizophrenia/.

ClinicalTrials.gov. A clinical study that will measure how well SEP-363856 works and how safe it is in adults with generalized anxiety disorder. Sumitomo Pharma America, Inc.; 2023. p. NCT05729373. Report No.

ClinicalTrials.gov. A trial of the Safety and Efficacy of SEP-363856 in the treatment of adults with Major Depressive Disorder. Otsuka Pharmaceutical Development & Commercialization, Inc.; 2022 09 November 2022. Report No.: NCT05593029.

Hernandez CC, Klassen TL, Jackson LG, Gurba K, Hu N, Noebels JL, Macdonald RL. Deleterious rare variants reveal risk for loss of GABAA receptor function in patients with genetic Epilepsy and in the General Population. PLoS ONE. 2016;11(9):e0162883.

Article  PubMed  PubMed Central  Google Scholar 

John J, Kukshal P, Bhatia T, Chowdari KV, Nimgaonkar VL, Deshpande SN, Thelma BK. Possible role of rare variants in Trace amine associated receptor 1 in schizophrenia. Schizophr Res. 2017;189:190–5.

Article  PubMed  PubMed Central  Google Scholar 

Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, et al. Serotonin subtype 2 receptor genes and clinical response to Clozapine in Schizophrenia patients. Neuropsychopharmacology. 1998;19(2):123–32.

Article  CAS  PubMed  Google Scholar 

Shastry BS. SNPs in disease gene mapping, medicinal drug development and evolution. J Hum Genet. 2007;52(11):871–80.

Article  CAS  PubMed  Google Scholar 

Fowler S, Kletzl H, Finel M, Manevski N, Schmid P, Tuerck D, et al. A UGT2B10 splicing polymorphism common in African populations may greatly increase drug exposure. J Pharmacol Exp Ther. 2015;352(2):358.

Article  PubMed  Google Scholar 

Mühlhaus J, Dinter J, Jyrch S, Teumer A, Jacobi SF, Homuth G et al. Investigation of naturally occurring single-nucleotide variants in Human TAAR1. Front Pharmacol. 2017;8.

Rutigliano G, Zucchi R. Molecular variants in Human Trace Amine-Associated receptors and their implications in Mental and Metabolic disorders. Cell Mol Neurobiol. 2020;40(2):239–55.

Article  PubMed  Google Scholar 

Loftis JM, Lasarev M, Shi X, Lapidus J, Janowsky A, Hoffman WF, Huckans M. Trace amine-associated receptor gene polymorphism increases drug craving in individuals with methamphetamine dependence. PLoS ONE. 2019;14(10):e0220270.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi X, Walter NA, Harkness JH, Neve KA, Williams RW, Lu L, et al. Genetic polymorphisms affect mouse and human Trace Amine-Associated receptor 1 function. PLoS ONE. 2016;11(3):e0152581.

Article  PubMed  PubMed Central  Google Scholar 

Liu H, Zheng Y, Wang Y, Wang Y, He X, Xu P et al. Recognition of methamphetamine and other amines by trace amine receptor TAAR1. Nature. 2023.

Shang P, Rong N, Jiang JJ, Cheng J, Zhang MH, Kang D et al. Structural and signaling mechanisms of TAAR1 enabled preferential agonist design. Cell. 2023.

Xu Z, Guo L, Yu J, Shen S, Wu C, Zhang W et al. Ligand recognition and G protein coupling of trace amine receptor TAAR1. Nature. 2023.

Zilberg G, Parpounas AK, Warren AL, Yang S, Wacker D. Molecular basis of human trace amine-associated receptor 1 activation. Nat Commun. 2024;15(1):108.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nair PC, Shajan B, Bastiampillai T. Newly identified structures of trace-amine associated receptor-1 (TAAR1) will aid discovery of next generation neuropsychiatric drugs. Mol Psychiatry. 2024.

Nair PC, Miners JO, McKinnon RA, Langmead CJ, Gregory KJ, Copolov D, et al. Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs. Mol Psychiatry. 2022;27(1):88–94.

Article  CAS  PubMed  Google Scholar 

Mailman MD, Feolo M, Jin Y, Kimura M, Tryka K, Bagoutdinov R, et al. The NCBI dbGaP database of genotypes and phenotypes. Nat Genet. 2007;39(10):1181–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zakharia F, Basu A, Absher D, Assimes TL, Go AS, Hlatky MA, et al. Characterizing the admixed African ancestry of African americans. Genome Biol. 2009;10(12):R141.

Article  PubMed  PubMed Central  Google Scholar 

Liu X, Li C, Mou C, Dong Y, Tu Y. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med. 2020;12(1):103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sim N-L, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40(W1):W452–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics. 2015;31(16):2745–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 2011;39(17):e118–e.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4):361–2.

Article  CAS